Aryastha Life Sciences (AALS) is a premier preclinical research organization. Welcome to AALS where science meets safety. We are your trusted partner in delivering comprehensive toxicology services that support the development of safe and effective pharmaceuticals, biologics, and chemicals.”
“Our mission is to provide high-quality, GLP-compliant toxicology studies that accelerate your product development while ensuring regulatory compliance and patient safety.”
- We offer a full spectrum of In-vitro and In-vivo toxicology services including :
- General Toxicology (acute, sub-chronic, chronic)
- Reproductive and Developmental Toxicology
- Genetic Toxicology
- Carcinogenicity Studies
- Immunotoxicology
- Juvenile Toxicity
- Safety Pharmacology
- Local Tolerance Studies
An Unmatched Advantage: World’s Largest Supply of Large Animals
One of Aryastha’s greatest strengths lies in our unparalleled access to a broad range of animal models. Our facilities house the world’s largest supply of large animals for toxicology studies, including rodents, dogs, and non-human primates. This vast access not only ensures the reliability and validity of your studies but also allows us to offer more tailored and comprehensive study designs.
In addition, our animal care programs adhere to the highest global standards, and our experienced veterinary staff ensure that animal welfare remains our top priority. This ethical commitment and resource depth set Aryastha apart as your go-to partner for conducting complex toxicology studies with confidence.
- Our advanced capabilities include :
- Biomarker analysis
- Bioanalytical support
- Histopathology and digital pathology
- Inhalation and dermal exposure studies
- Microbiome and immunotoxicology integration
- TK/PK sampling and analysis
Whether you’re advancing a small molecule, biologic, or novel therapy, we’re here to support your journey from discovery to approval. Let’s build safer science together.
In vitro assessments of toxicity
In vitro toxicity assessments identify compounds expected to fail due to safety concerns. Tests such as the Ames test, coupled with evaluations for mutagenicity and carcinogenicity, including screening for the hERG channel, help filter out problematic compounds. Compounds that interfere with the hERG channel can lead to irregular heartbeats, ventricular fibrillation, and even fatalities.
In vitro Safety Pharmacology Screening
Safety pharmacology screening focuses on early hazard identification and subsequent compound profiling to guide preclinical in vivo and clinical safety studies.
Over 100 kinases
IC50 determination
Kinases: full-length or catalytic domain
Wild type and mutated versions
Multiple readouts (ADP-Glo, Lantha, etc.)
Multiple formats: calcium flux, cAMP, radioligand-based binding
A single dose or dose response for EC50 and IC50 determination
Selected targets relevant to clinical adverse drug reactions (ADR)
Toxicology Services
Exploratory, GLP and Regulatory Toxicity Studies
- General toxicology studies
- Acute toxicity studies
- Acute inhalation study
- Acute parenteral toxicity studies
- Local tolerance studies
- Mucous membrane irritation
- Ocular irritation
- Single-dose study
- Skin irritation
- Sub-acute toxicity studies
- Repeat dose 7, 14, 21, 28, and 42-day studies
- Sub-chronic toxicity studies
- Repeat dose 90-day studies
- Chronic toxicity studies
- Repeat dose 120 and 180-day studies
- Genetic toxicology studies
- In Vitro Chromosomal Aberration Test
- In Vitro Cytotoxicity Test
- In Vitro Eye Irritation Test
- In Vitro Micronucleus Test
- In Vitro Phototoxicity Test
- In Vitro Skin Corrosion Test
- In Vitro Skin Irritation Test
- Bone Marrow Chromosome Aberration Test
- Mutation Test – AMES Test
- Micronucleus Test in rodents
- Reproductive and Developmental toxicity
- Embryo fetal development studies
- Fertility and early embryonic development in rodents
- Pre and postnatal development in rodents
- Immunotoxicity
- Immunosuppression or stimulation assays (usally required for immunomodulatory drugs
- Immunotoxicity assays (e.g., cytokine release, immune cell profiling, T-cell/B-cell function assays)
- Lymphoid organ histopathology
- Carcinogenicity
- Long-term studies in rodents (usually 2-year studies)
- Required for drugs intended for chronic use
- Local Tolerance Studies
- Assess irritation or damage at the site of administration (e.g., dermal, ocular, parenteral)
- Safety Pharmacology studies
- Cardiovascular system studies (e.g., hERG assay, QT interval, telemetry in animals)
- Central nervous system studies (behavioural, motor activity)
- Respiratory system studies (respiratory rate, tidal volume)
- Exploratory and Discovery toxicology
- General toxicology studies
- Dose-range finding studies
- Repeat-dose toxicity studies
- Pharmacokinetic and Toxicokinetic studies (PK/TK)
- ADME (Absorption, Distribution, Metabolism, Excretion)
- Helps correlate exposure with toxic effects
- Histopathology and Clinical chemistry
- Clinical chemistry analysis
- Gross pathology
- Hematology and coagulation analysis
- Histopathology
- immunohistochemistry techniques
- Urinalysis
Ready to Take the Next Step?
Contact us now for a free, confidential proposal and see why direct experience with Aryastha’s team is the difference you’ve been searching for.
Your path to successful IND-enabling studies starts here.
